Compare Palantir Technologies Inc (PLTR) vs Viatris Inc (VTRS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Palantir Technologies Inc vs Viatris Inc — how do they compare? Palantir Technologies Inc trades at $124.82 (market cap $318.03B), while Viatris Inc trades at $17.02 (market cap $20.50B). The key difference: Palantir Technologies Inc is far larger — about 15.5× Viatris Inc's market cap, and Viatris Inc pays a 2.73% dividend while Palantir Technologies Inc pays none. Which is the better fit depends on your goals.
| PLTR | VTRS | |
|---|---|---|
Market Cap | $318.03B | $20.50B |
Sector | Technology | Health |
52-Week High | $207.18 | $17.59 |
52-Week Low | $107.27 | $8.74 |
Enterprise Value | $310.21B | $32.71B |
Dividend Yield | — | 2.73% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Palantir (PLTR) trades at $132.62, up 0.18% on the day, with a bullish technical signal from moving averages but overbought RSI readings. The company reported strong earnings beats in recent quarters, with Q1 2026 EPS of $0.33 exceeding expectations. Revenue grew to $4.48 billion in 2025, and net income surged to $1.63 billion, reflecting robust profitability. Analyst sentiment is mixed, with a consensus price target of $185.75 and 46% of analysts rating it a Buy.
Outlook: PLTR's accelerating revenue growth and expanding margins support long-term upside, but high valuation multiples (P/E 151.52, P/S 66.33) pose risks if growth slows. Key catalysts include continued AI adoption and execution on guidance. Risks include competitive pressures and market volatility. The stock offers growth potential but requires tolerance for premium valuation and earnings sensitivity.
Viatris (VTRS) trades at $17.59, up 1.74% today, with a bullish technical signal and consistent earnings beats in recent quarters. The company reported revenue of $14.3B for 2025 but posted a net loss of $3.51B, reflecting margin pressures. Positive pipeline developments include FDA acceptance of a new drug application for fast-acting meloxicam, with a PDUFA date set for December 2026. Cash flow from operations remains strong at $2.32B, supporting debt reduction efforts.
The outlook is mixed: analyst consensus targets $20.00 (13.7% upside), but profitability challenges and high debt levels pose risks. Investment appeal hinges on successful pipeline execution and margin recovery, while competitive and regulatory pressures in the generics market remain key watchpoints for shareholders.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Palantir Technologies Inc
Palantir Technologies provides organizations with solutions to manage large disparate data sets in an attempt to gain insight and drive operational outcomes. Founded in 2003, Palantir released its Gotham software platform in 2008, which focuses on the government intelligence and defense sectors. Palantir expanded into various commercial markets with its Foundry software platform in 2016 with the intent of becoming the data operating system for companies and industries. The Denver company had 125 customers as of its initial public offering and roughly splits its revenue between commercial and government customers.
Read more on PLTR →About Viatris Inc
Formed by the combination of Mylan and Pfizer's Upjohn business in 2020, Viatris is one of the world's largest generic drug manufacturers, with a substantial off-patent branded drug portfolio. Its portfolio consists of more than 1,400 molecules with penetration across most of the developed world and in select emerging markets. The company's branded drug portfolio consists of off-patent blockbuster drugs that continue to generate strong sales, including Lipitor, Norvasc, Lyrica, Viagra, and EpiPen. While global competition has facilitated the commodification of small-molecule generic drugs, the company has demonstrated an edge over peers in its ability to manufacture complex generics (for example, generic Advair and Copaxone).
Read more on VTRS →
